Please use this identifier to cite or link to this item:
Title: RET-rearranged non-small-cell lung cancer and therapeutic implications.
Austin Authors: Loh, Zoe ;Mitchell, Paul L R ;John, Thomas ;Arulananda, Surein
Affiliation: Department of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia
School of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australia
Issue Date: Dec-2019
Publication information: Internal Medicine Journal 2019; 49(12): 1541-1545
Abstract: First-line tyrosine kinase inhibitors are standard of care for non-small-cell lung cancers (NSCLC) harbouring an epidermal growth factor receptor mutation, anaplastic lymphoma kinase fusion or c-ros oncogene 1 rearrangement. Other targetable oncogenic drivers have been identified but testing for these is neither funded nor commonly performed in Australia. Using a case example, we discuss the importance of considering several other genomic aberrations in our population, such as rearrangements in the RET proto-oncogene, which occur in 1-2% of lung adenocarcinoma. New oncogenic drivers and corresponding targeted agents are constantly being discovered; these will continue to refine the treatment of non-small-cell lung cancer in the era of precision medicine.
DOI: 10.1111/imj.14654
ORCID: 0000-0002-9215-1441
Journal: Internal Medicine Journal
PubMed URL: 31808254
Type: Journal Article
Subjects: RET rearrangement
genomic profiling
non-small-cell lung cancer
tyrosine kinase inhibitor
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Feb 3, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.